Smoking Cessation and Nicotine Addiction Market Summary
The Smoking Cessation and Nicotine Addiction market continues to evolve rapidly, driven by increasing awareness of tobacco-related health consequences, expanding pipeline therapies, and growing governmental and institutional support for cessation programs. According to the latest analysis, the market is poised for significant growth through the forecast period of 2024–2034, with novel treatment candidates reshaping the therapeutic landscape across the Seven Major Markets (7MM) – the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Key highlights from the analysis include:
- The majority of Prevalent Cases of Smoking Cessation were estimated in the US, followed by EU4, the UK, and Japan, whereas the highest cases of tobacco use were recorded in EU4 and the UK among all studied regions.
- In 2023, the Smoking Cessation and Nicotine Addiction Market Size was highest in the US among the 7MM, accounting for approximately USD 1,472 million, and lowest in Germany at USD 46 million – both figures are expected to shift considerably by 2034.
- The total Smoking Cessation and Nicotine Addiction Treatment Market Size is anticipated to experience robust growth during the forecast period (2024–2034), driven by emerging treatments including cytisinicline, AXS-05, and NFL-101.
- Gender-specific prevalent cases of tobacco use were notably higher in males (approximately 31,040 thousand cases) compared to females (approximately 19,846 thousand cases) in 2023 in the US alone.
Smoking Cessation and Nicotine Addiction Epidemiology
Grounded in a rigorous patient-based model, the epidemiology analysis provides both historical and forecasted data spanning 2020 to 2034. The segmentation covers Prevalent Cases of Tobacco Use, Gender-specific Prevalent Cases, Age-specific Prevalent Cases, Tobacco Use by Product Type, Prevalent Nicotine Dependent Cases Among Cigarette Smokers, and Prevalent Cases of Smoking Cessation across the 7MM.
Delving into regional breakdowns, the Smoking Cessation and Nicotine Addiction market research reveals the following:
- EU4 and the UK collectively accounted for approximately 63,953 thousand prevalent cases of tobacco use – the highest across all studied regions – followed by the US with around 50,886 thousand cases and Japan with approximately 20,185 thousand cases in 2023. These figures are projected to decline across all regions by 2034, reflecting the anticipated impact of cessation programs and newer therapies.
- Within EU4 and the UK, Germany recorded the highest prevalent cases of tobacco use at approximately 18,101 thousand cases, followed closely by France at around 16,429 thousand cases. In contrast, the UK reported the lowest at 8,788 thousand cases – the lowest among all EU4 and the UK countries within the 7MM.
- Tobacco use remains male-dominant across the 7MM. In 2023, approximately 59% of all prevalent tobacco use cases were among males, while approximately 41% were among females – underscoring the importance of gender-targeted cessation strategies.
- Age-specific data further highlights the concentration of tobacco use among working-age adult populations, reinforcing the urgent need for accessible and effective treatment options across demographics.
Smoking Cessation and Nicotine Addiction Drug Analysis
A critical pillar of Smoking Cessation and Nicotine Addiction market insight lies in understanding the current and future therapeutic landscape – from well-established marketed drugs to late-stage pipeline candidates showing significant promise.
Smoking Cessation and Nicotine Addiction Marketed Drugs
CHANTIX/CHAMPIX (varenicline) – Pfizer Varenicline tartrate, a nicotinic receptor partial agonist, remains one of the most widely prescribed smoking cessation aids globally. Approved by the US FDA in May 2006 as the first oral non-nicotine smoking cessation treatment, it works by simultaneously blocking the reinforcing effects of nicotine and alleviating withdrawal symptoms. It has received regulatory approvals in the EU4, the UK, and Japan. NICE recommended CHAMPIX for NHS use in May 2007. A significant accessibility milestone was reached in August 2021 when the FDA approved the first generic version, developed by Par Pharmaceutical, available in 0.5 mg and 1 mg formulations.
ZYBAN (bupropion hydrochloride) – GlaxoSmithKline Originally developed as an antidepressant, ZYBAN’s smoking cessation properties were identified in 1997, establishing it as a frontline non-nicotine cessation therapy. Operating through noradrenergic and dopaminergic pathways, it selectively inhibits neuronal reuptake of catecholamines. In May 2010, Mylan Pharmaceuticals secured FDA approval for a generic formulation, enhancing affordability and patient access.
Smoking Cessation and Nicotine Addiction Emerging Drugs
- Cytisinicline (cytisine) – Achieve Life Sciences: An oral, plant-based alkaloid with strong binding affinity to nicotinic acetylcholine receptors. With over two decades of use in Central and Eastern Europe, cytisinicline has completed a Phase III study evaluating 3 mg thrice daily over 42 days. An additional Phase III study (ORCA-OL) is ongoing, and Phase II evaluation in e-cigarette users is also underway – reflecting expanding indications.
- NFL-101 – NFL Biosciences SAS: A patented botanical drug candidate derived from natural tobacco leaf proteins. Delivered via two subcutaneous injections one week apart, NFL-101 has demonstrated safety and long-term cessation efficacy in Phase I/II trials without compensatory smoking behavior. NFL Biosciences partnered with the CEA in February 2023 to study its mechanism through molecular imaging, and earlier with Diverchim in November 2021 for GMP-compliant ingredient development.
- EMB-001 – Embera NeuroTherapeutics, Inc.: A patented combination of metyrapone and oxazepam designed to target the stress response pathway underlying addiction and relapse. Phase II clinical development was supported by a USD 11.1 million NIDA grant. Notably, EMB-001 demonstrated a statistically significantly greater effect compared to varenicline in nicotine cessation studies – a finding that could reshape competitive dynamics in the market.
Smoking Cessation and Nicotine Addiction Recent Developments
- In February 2023, NFL Biosciences collaborated with the CEA to examine NFL-101’s mechanism of action using advanced molecular imaging techniques.
- Achieve Life Sciences progressed its ORCA-OL Phase III study for cytisinicline, with continued enrollment among adult smokers seeking cessation support.
- Embera NeuroTherapeutics advanced EMB-001 through Phase II funding secured from the Foundation for a Smoke-Free World and the Rose Research Center (RRC) in North Carolina.
- Phase IIb (CESTO 2) efficacy results for NFL-101 were anticipated in mid-2024, generating significant anticipation within the research and investment communities.
- The FDA’s approval of generic varenicline and bupropion formulations continues to influence prescribing patterns and market access dynamics across the US.
Smoking Cessation and Nicotine Addiction Leading Companies
The competitive landscape of the Smoking Cessation and Nicotine Addiction market trends is shaped by a diverse mix of established pharmaceutical players and innovative biotechs. The leading companies currently advancing therapies include:
- Achieve Life Sciences
- NFL Biosciences SAS
- Embera NeuroTherapeutics, Inc.
- Axsome Therapeutics
- Currax Pharmaceuticals LLC
- Omeros Corporation
- Promentis Pharmaceuticals
- Otsuka Pharmaceutical
These organizations are investing substantially in clinical development and strategic collaborations to address the significant unmet need that persists within the cessation space – particularly among treatment-resistant and high-dependency patient populations.
Conclusion
The global smoking cessation and nicotine addiction landscape is undergoing a meaningful transformation. Despite decades of established therapies such as varenicline and bupropion, a substantial treatment gap remains – and the emerging pipeline signals a new era of more targeted, efficacious, and accessible interventions. With market valuations expected to grow well beyond the 2023 benchmarks and epidemiological trends indicating a gradual but sustained decline in tobacco use across the 7MM, the next decade will be defining for the industry.
Stakeholders – from pharmaceutical developers and payers to healthcare providers and policymakers – stand at a pivotal juncture where the convergence of scientific innovation and public health imperatives creates compelling opportunity. The trajectory of this market will not only reflect commercial dynamics but also the collective global commitment to reducing tobacco-related disease burden.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
